NCT05081336

Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: University Clinical Centre of Republic of Srpska · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular adverse events following acute coronary syndrome (ACS). However, the data coming from the real-world setting are limited. Therefore, the aim of the study is to assess the association between LDL-C changes with prognosis in patients who survive ACS. Patients with ACS will be followed for mortality and major events for at least 1 year. Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed. The associations between quartiles of LDL-C change and therapy intensity with outcomes will be investigated using adjusted Cox regression analyses.

Conditions

• Acute Coronary Syndrome
• Dyslipidemias

Interventions

Type	Name	Description
DRUG	Statin	Statin +/- ezetimib +/- Alirocumab

Timeline

• Start date: 2021-03-01
• Primary completion: 2023-01-01
• Completion: 2023-03-01
• First posted: 2021-10-18
• Last updated: 2021-10-25

Locations

1 site across 1 country: Bosnia and Herzegovina